Laura Shawver, Silverback CEO
July 21, 2022 04:07 PM EDTUpdated 05:19 PM
Deals

Or­biMed-backed Sil­ver­back, three months af­ter hack­ing the pipeline, re­verse-merges with small al­ler­gy biotech

Paul Schloesser

Associate Editor

Six years af­ter be­ing found­ed, a Seat­tle biotech backed by Or­biMed is say­ing good­bye in a clas­sic re­verse merg­er — while an­oth­er jumps to Nas­daq. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times